BioNTech Snags $320m, Roche/Spark Delay, & Summer Job Switches

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

AbbVie & Allergan (Groan), Adaptive Headlines IPO Rush, & FDA Cops on the Beat
Pfizer’s Wager on Small Molecules, Summer IPO Flurries, Gilead’s Protein Degrader Play
Amgen Swings for the RAS Fence, Gilead’s Grilling on Price, & Agios Enlarges the Pie
Thermo Bets on Viral Vector Manufacturing, Precision & Genfit’s IPOs, & Not Much Else